{"id":13355,"date":"2026-01-05T20:31:58","date_gmt":"2026-01-05T17:31:58","guid":{"rendered":"https:\/\/investn24.com\/?p=13355"},"modified":"2026-01-05T20:31:58","modified_gmt":"2026-01-05T17:31:58","slug":"wegovy%ef%b8%8f-pill-approved-in-the-us-as-first-oral-glp-1-for-weight-management","status":"publish","type":"post","link":"https:\/\/investn24.com\/?p=13355","title":{"rendered":"Wegovy\u00ae\ufe0f pill approved in the US as first oral GLP-1 for weight management"},"content":{"rendered":"
\"\"<\/div>\n
<\/div>\n
Wegovy\u00ae\ufe0f pill showed a mean weight loss of 16.6% in the OASIS 4 trial<\/div>\n
Wegovy\u00ae\ufe0f pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events*<\/div>\n
Novo Nordisk expects to launch Wegovy\u00ae\ufe0f pill in the US in early January 2026<\/div>\n
<\/div>\n
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy\u00ae\ufe0f pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.<\/div>\n
The Wegovy\u00ae\ufe0f pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS trial programme and the SELECT trial2. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities1. The weight loss achieved with the Wegovy\u00ae\ufe0f pill is similar to that of injectable Wegovy\u00ae\ufe0f 2.4 mg. Furthermore, one in three people experienced 20% or greater weight loss in the OASIS 4 trial1. The well-known safety and tolerability profile of semaglutide was reaffirmed with the Wegovy\u00ae\ufe0f pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management.<\/div>\n
\u00a0\u201cThe pill is here. With today’s approval of the Wegovy\u00ae\ufe0f pill, patients will have a convenient, oncedaily pill that can help them lose as much weight as the original Wegovy\u00ae\ufe0f injection,\u201d said Mike Doustdar, president and CEO of Novo Nordisk. \u201cAs the first oral GLP-1 treatment for people<\/div>\n
living with overweight or obesity, the Wegovy\u00ae\ufe0f pill provides patients with a new, convenient treatment option that can help patients start or continue their weight loss journey. No other current oral GLP-1 treatment can match the weight loss delivered by the Wegovy\u00ae\ufe0f pill, and we are very excited for what this will mean for patients in the US\u201d.<\/div>\n
Novo Nordisk expects to launch the Wegovy\u00ae\ufe0f pill in the US in early January 2026. Novo Nordisk has submitted oral semaglutide 25 mg once-daily for obesity to the European Medicines Agency (EMA) and other regulatory authorities during the second half of 2025.<\/div>\n","protected":false},"excerpt":{"rendered":"

Wegovy\u00ae\ufe0f pill showed a mean weight loss of 16.6% in the OASIS 4 trial Wegovy\u00ae\ufe0f pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events* Novo Nordisk expects to launch Wegovy\u00ae\ufe0f pill in the US in early January 2026 Novo Nordisk today<\/p>\n","protected":false},"author":10,"featured_media":13353,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"post-13355","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-1"},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/posts\/13355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/investn24.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13355"}],"version-history":[{"count":1,"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/posts\/13355\/revisions"}],"predecessor-version":[{"id":13356,"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/posts\/13355\/revisions\/13356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/investn24.com\/index.php?rest_route=\/wp\/v2\/media\/13353"}],"wp:attachment":[{"href":"https:\/\/investn24.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/investn24.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/investn24.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}